Clinical Trial Update: Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of sugammadex (MK-8616) in participants with moderate to severe renal insufficiency completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment
• Renal Insufficiency

Drugs mentioned

• Sugammadex (sugammadex)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Insufficiency, Renal Impairment | Phase 1 | Status: COMPLETED | Results posted: 2015-02-10